Table 1 Characteristics of randomised controlled trials included in the meta-analysis
Study/year | Patients no. (I/C) | Cancer type | Age, mean, years (I/C) | Intervention group | Control group | Primary outcome | Secondary outcomes | Study design/Jadad score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type of PR | Time/session | Frequency | Intensity | Duration | ||||||||
Arbane et al., [15] | 51 (26/25) | NSCLC | 65.4/62.6 | Strength and mobility training | 5–10 min | Twice daily | 60–80% MHR | 12 weeks + 5 days | Usual care | 6MWD | POC, QoL, quadriceps strength | RCT/4 |
Arbane et al., [20] | 131 (64/67) | NSCLC | 67/68 | Hospital plus home exercise | 30 min | Once daily | 60–90% MHR | 4 weeks | Usual care | Physical activity | POC, QoL, quadriceps strength | RCT/4 |
Brocki et al., [43] | 78 (41/37) | NSCLC | 64/65 | Aerobic exercise + resistance training + dyspnoea management | NA | NA | 60–80% peak work capacity | 12 weeks | Usual care | QoL | 6MWD, FEV1 | RCT/3 |
Brocki et al., [16] | 68 (34/34) | NSCLC + metastatic tumour + other type | 69.7/70.5 | Inspiratory muscle training | NA | Twice daily | 30% of MIP | 2Â weeks | Standard physiotherapy treatment | Inspiratory muscle strength | 6MWD, FEV1, dyspnoea, POC | RCT/4 |
Edvardsen et al., [22] | 61 (30/31) | NSCLC | 64.4/65.9 | High-intensity endurance and strength training | 60 min | Three times a week | 80–95% MHR | 20 weeks | Standard postoperative care | Peak oxygen uptake | FEV1, QoL, muscular strength and mass | RCT/4 |
Stigt et al., [21] | 49 (23/26) | NSCLC | 63.6/63.2 | Aerobic (cycling) + resistance | 60 min | Twice weekly | 60–80% peak load | 12 weeks | Usual care | QoL | 6MWD, FEV1, pain | RCT/4 |